Sign In
Buy VNDA
$6.09
-0.0400 (-0.653%)
At Close: Jun 03, 2026
Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
07:00am, Wednesday, 27'th May 2026
WASHINGTON, May 27, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designatio
Vanda: A Long-Term Pharma Growth Idea, Despite Q1 Earnings Miss
01:34pm, Wednesday, 13'th May 2026
Vanda Pharmaceuticals is rated a buy, supported by new drug approvals, a diversified clinical pipeline, and strong top-line growth potential. VNDA's near-zero debt and undervalued price/book ratio off
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
06:44pm, Thursday, 07'th May 2026
WASHINGTON, May 7, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in May 2026:
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
05:01am, Thursday, 07'th May 2026
Vanda Pharmaceuticals Inc. (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
06:11pm, Wednesday, 06'th May 2026
Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to a loss of $0.5 per share a year ago.
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
04:01pm, Wednesday, 06'th May 2026
Fanapt ® net product sales rose 26% to $29.6 million; total prescriptions increased 32% and new-to-brand prescriptions surged 76% NEREUS™ (tradipitant) launched via nereus.us, an innovative direct-
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
10:55am, Tuesday, 05'th May 2026
The mean of analysts' price targets for Vanda (VNDA) points to a 105% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now co
Consumers can now order NEREUS™ directly at nereus.us WASHINGTON, May 1, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that NEREUS™ (tradipitant) is now co
Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
04:30pm, Wednesday, 29'th Apr 2026
Conference Call and Webcast to Follow WASHINGTON, April 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2026 on
WASHINGTON, April 28, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of the original research article titled "Efficacy and Safety of Imsidolimab
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
09:16am, Tuesday, 28'th Apr 2026
Incyte (INCY) came out with quarterly earnings of $1.81 per share, beating the Zacks Consensus Estimate of $1.38 per share. This compares to earnings of $1.16 per share a year ago.
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
05:13pm, Wednesday, 22'nd Apr 2026
WASHINGTON, April 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the appointment of Charles Duncan, Ph.D. to its Board of Directors effective April 22, 202
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average – Time to Sell?
03:20am, Tuesday, 21'st Apr 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday. The stock has a 200-day moving average of $6.67 and traded
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Sees Significant Increase in Short Interest
02:20am, Wednesday, 15'th Apr 2026
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totaling 5,310,26
